Speakers

Abel Ang

Adjunct Professor and Chairperson, Advanced MedTech Investments

Ang is the chairperson of Advanced MedTech Investments. Between 2014 and 2024, he led Advanced MedTech - Temasek Holding's US$335M global platform in urology devices and services. As Founding President and Group CEO, he transformed the carved-out medical device platform from a loss-making unit to a top performer (IRR-returns) within Temasek’s portfolio. He drove significant revenue growth by transforming the group’s product portfolio, achieving a 4-fold increase during his tenure, while simultaneously increasing EBITDA by 33 times without any additional capital from shareholders.

Ang boasts a proven track record of medtech innovation, having brought 100 distinct devices to market globally. He specializes in accelerating R&D productivity and scaling commercial organizations to extract maximum value from new product innovation, especially in the US. Advanced MedTech’s US revenue grew 10-fold during his tenure to US$200M with an annual growth-rate of 22.3% in 2024.

He served as Senior Advisor to the CEO of Greatbatch Inc. (NYSE: ITGR), supporting innovation across cardiac, neurology, vascular, and orthopedic markets. Prior to this, Ang led Hill-Rom Inc., a $3B medical device company (acquired by BAX), as President, Asia/Pacific. As Hill-Rom's Chief Technology Officer, he oversaw global R&D operations spanning the U.S., Mexico, France, and Singapore. He also held key leadership roles including Vice-President and General Manager of the $420M Global Therapy Business Unit and Vice-President for International M&A. He formerly headed the global Medical Technology and Biotechnology industry groups in the Singapore Economic Development Board (EDB).

Ang sits on the Board of Economic Development Innovations Singapore, a privately-held investment holding company headquartered in Singapore with investments in deeptech and listed assets. He sits on the Boards of Advanced MedTech Holdings, SonoMotion Inc., ABM Respiratory Inc., and Vivance(formerly AWAK Technologies), where he chairs the Board. He was formerly on the Board and Nominating Committee of Aslan Pharmaceuticals (NYSE: ASLN).

On the education front, Ang is an adjunct full-professor at the Nanyang Business School in Singapore and Waseda University in Japan, where he teaches in their respective MBA programs. He is Chairman of Republic Polytechnic and Vice-Chairman of Singapore Institute of Management that collectively have 30,000 full-time higher education students. Ang has a Master of Science in Computational Biology from Rutgers University in New Jersey, which he pursued while on an EDB scholarship. He attended Harvard Business School’s Advanced Management Program in 2012.

He was awarded the Public Service Medal (PBM) in 2021 for his contributions to the medical device industry in Singapore. He was again awarded the Public Service Medal (COVID-19) in 2022 for his innovative achievements during COVID.

Ang is married and has 2 grown boys. He writes a regular column in The Straits Times and wing-foils in his free time.

Wing Lok Au

Chief Executive Officer and Senior Consultant Neurologist, National Neuroscience Institute

Professor Au Wing Lok is the Chief Executive Officer of Singapore's National Neuroscience Institute (NNI) and a Senior Consultant Neurologist. After graduating from the National University of Singapore, he completed his specialist training at NNI before advancing his expertise through a two-year Movement Disorders Fellowship at Canada's Pacific Parkinson's Research Centre. He also received specialised training in electrophysiology (the study of electrical activity in the nervous system) at Toronto Western Hospital, Canada.

Assoc Prof Au sees patients at NNI@TTSH and specialises in treating patients with Parkinson's disease and various movement disorders. He is trained in administering botulinum toxin injections (medication injections that help relax overactive muscles) for conditions such as:

- Hemifacial spasm (involuntary twitching or contractions of facial muscles)

- Blepharospasm (uncontrollable blinking or closure of the eyes)

- Dystonia (sustained muscle contractions causing unusual postures or repetitive movements)

- Spasticity (continuous muscle stiffness and tightness)

His research focuses on functional neuroimaging (advanced brain scanning techniques) and electrophysiology in Parkinson's disease, working to better understand how the brain functions in patients with movement disorders.

As the leader of NNI, A/Prof Au believes that employee wellness is key so that staff can give their best to their patients. He received the WorkWell Leaders Wellbeing CEO Award 2025 for prioritising staff mental wellbeing and creating a more resilient and supportive workplace at NNI.

Michael Chee

Director, Centre for Sleep and Cognition, NUS Yong Loo Lin School of Medicine

Professor Michael Chee, MBBS, FRCP(Edin) is the Director of Centre for Sleep and Cognition at the National University of Singapore Yong Loo Lin School of Medicine. He is a pioneer clinician-scientist in Singapore who has won the National Outstanding Clinician-Scientist Award (2009) and is a three-time award winner of the National Medical Research Council’s top tier Clinician-Scientist STaR award (2007, 2013, 2019). He is an inaugural Fellow of the Organisation for Human Brain Mapping.

As an esteemed Sleep Researcher, Professor Michael Chee’s work on sleep over the last 20 years has focused on characterising and alleviating the negative impact of sleep deprivation on cognitive performance, wellbeing and health using innovative cognitive tests as well as a wide range of instrumentation including EEG, MRI, wearable devices, and ecological momentary assessments. His team ran 5 editions of the adolescent ‘Need for Sleep Studies’ – a 2-week sleep camp investigating the effects of different doses of sleep on vigilance, memory and mood.

Renowned as a leading Sleep Researcher, he has led work on non-invasive stimulation technologies to enhance sleep, a series of intervention studies involving sleep education and starting school later to help adolescents sleep longer, developed smartphone apps to assess time use and to probe sleep and daytime wellbeing, as well as multiple papers investigating the neural mechanisms of sleep loss as well as the benefit of naps. His 200+ publications include contributions to Ann Rev Psychol, PNAS, Neuron, J Neuroscience, Am J Psychiatry, Neurology, Sleep and NeuroImage. His research has attracted over $50 million in funding as Principal Investigator.

In the sleep field, he has served as Vice President (2013-2014) and President (2016-2018) of the Singapore Sleep Society, given plenary or keynote talks at top conferences such as World Sleep, Organization for Human Brain Mapping and the American Academy of Sleep Medicine, consulted for AIA and presently sits on the editorial boards of Sleep, Imaging Neuroscience and Current Opinion in Behavioral Sciences.

He has also written numerous commentaries on sleep and public health and has appeared on television, internet, and international print media in relation to his advocacy work for sleep, which has been cited by the Times, Guardian, Economist, and other influential lay press publications. He has also trained over 80 research staff including 4 Associate Professors, 7 Assistant Professors, numerous research fellows as well as a few medical doctors, clinical psychologists, and founders of two tech start-ups.

Irene Cheong

Assistant Chief Executive (Innovation and Enterprise), Agency for Science, Technology and Research

Ms Irene Cheong is the Assistant Chief Executive, Innovation & Enterprise (I&E), at A*STAR. She provides operational leadership to the I&E Group and National Platforms and drives I&E's daily operations. She also leads A*STAR's industry engagements, catalysing more impactful A*STAR spin-offs and growing significant value in A*STAR's existing start-up portfolio.

Since joining A*STAR, Ms Cheong has led productisation and alignment efforts in MedTech, while putting in place strong programmes and partnerships to jumpstart A*STAR's venture building and spin-off capabilities. As Acting CEO, DxD Hub, Ms Cheong also oversees numerous collaborations with clinicians, scientists and companies to co-develop medically regulated diagnostics from early-stage biomarker validation through validation into regulatory and manufacturing. Ms Cheong holds core capabilities in biotech, medtech and diagnostics domains as well as industry development and venture creation.

Ms Cheong has prior experience in both the public, private sector and has proven herself to be strong in developing industry-academia partnerships across both the biomedical and physical sciences sectors. She founded and delivered on several noteworthy venture building programmes at the National University of Singapore (NUS), such as the Lean LaunchPad, JUMPStart and Graduate Research Innovation Programme (GRIP). She is experienced in developing start-up ecosystems and early-stage biotech and medtech investments, having been at EDB Investments based in San Francisco, and running sales and marketing for AstraZeneca based in Brussels and London. Prior to joining A*STAR, Ms Cheong helmed the Industry Liaison Office at NUS where she led technology commercialisation, industry collaborations and venture development programmes.

She is currently A*STAR's representative on numerous committees, including the steering committee for the NTU-NHG-A*STAR start-up space, co11ab, board oversight committee for Cardiovascular Disease National Collaborative Enterprise (CADENCE), SIP Joint Steering Committee and a council member of the Singapore-Jiangsu and Singapore-Guangdong Cooperation Councils, as well as selection committee member for the President's Technology Award, and MOE's IEOC Steering Committee.

Ms Cheong graduated with a Global Executive Master of Business Administration from NUS-UCLA, under a dual degree programme and a Master of Science, specialising in Microbiology. She also completed the Harvard Business School General Management Programme in 2023.

Rick Siow Mong Goh

Department Director of Computing and Intelligence, A*STAR Institute of High Performance Computing

Dr. Rick Goh is the Director of Computing & Intelligence Department at A*STAR’s Institute of High Performance Computing (IHPC), an Adj. Assoc. Professor at Duke-NUS Medical School, Adj. Senior Principal Investigator at Singapore Eye Research Institute (SERI), Co-Director of both A*STAR-EVYD Joint Lab and SERI-IHPC Joint Lab. He chaired the organising committee of HPC AI Innovation Challenge 2023-2024, organised by National Supercomputing Centre (NSCC), AI Singapore (AISG), and Infocomm Media Development Authority (IMDA).

Leading a team of 80 scientists and engineers, Dr. Goh focuses on world-leading scientific research, advancing technology commercialisation, and fostering industry collaborations. His dept specialises in Artificial Intelligence & Advanced Computing, including high performance computing using GPUs, FPGAs, quantum technologies, and decentralised computing like blockchain, secure multi-party computation and privacy-preserving federated learning. He has published 150+ peer-reviewed papers in prestigious healthcare journals including Nature Aging, Nature Genetics, The Lancet Digital Health, and top-tier AI journals and conferences such as Nature Machine Intelligence, Nature Comms, IEEE TPAMI, TNNLS, TPDS, Cybernetics, TMI, AAAI, CACM, CVPR, IJCAI, and MICCAI.

Under his leadership, his dept has won multiple highly competitive AI Singapore Tech Challenge and Grand Challenge grants, best paper awards, Global Challenge for Safe and Secure LLMs 2024, Singapore Blockchain Innovation Challenge 2024, RePSS Challenge 2024, and Singapore Healthcare Management Awards. His dept has secured over S$45M in industry cash and in-kind contributions, trained 150 researchers now working in academia or industry, spun off a startup that raised S$26M in investments and created 30 jobs, deployed a telehealth solution that saved 6,000 hospital bed days resulting in S$6M in cost savings, and was recognised with the Singapore National Award (COVID-19) Commendation Medal.

Creighton Heaukulani

Deputy Director and Principal Data Scientist, MOH Office for Healthcare Transformation

Dr. Creighton Heaukulani is Deputy Director and Principal Data Scientist at the MOH Office for Healthcare Transformation (MOHT) under the Ministry of Health in Singapore, where he leads the Digital Health Applications Team in the Data, Science & Technology Division, driving initiatives that transform care delivery and health promotion across the health system and in the community, with current focus on mental health and the management of chronic diseases.

He is also Adjunct Senior Lecturer in the Department of Statistics and Data Science at the National University of Singapore (NUS) where he lectures courses on machine learning.

Andy Hau Yan Ho

Provost’s Chair Professor in Psychology, Professor of Psychology & Medicine, Nanyang Technological University (NTU)

Professor Andy Hau Yan Ho, PhD, EdD, MFT a multi-award-winning psychologist, social scientist, and educator who specializes in thanatology, gerontology, psychotherapy, digital health, and community empowerment. He is Head of Psychology at Nanyang Technological University (NTU), President of the International End of Life Doula Association (INELDA), Past President of the Association for Death Education and Counseling (ADEC), and Fellow of the prestigious International Work Group on Death, Dying, and Bereavement (IWGDDB). A clinical innovator, Prof Ho has founded 15 acclaimed psycho-socio-spiritual interventions for health and mental health promotion, some of which include Mindful Compassion Art-based Therapy, Family Dignity Intervention, the WellFeet mHealth App, and the CADENCE Digital Personal Health Assistant. A prolific writer, he has authored over 180 top-tier research publications and 300 keynote and plenary presentations. His social and scholarly contributions are recognised with distinctions around the world.

Navjeewan Khosla

Partner, Novo Holdings

Nav joined Novo Holdings Asia in August 2021. He focusses on deal sourcing and execution as well as in managing and developing the growing portfolio of investments, focusing primarily on the markets in China, India, and Southeast Asia.

Prior to joining Novo Holdings Asia, Nav was a Director in Quadria Capital, a mid-market private equity firm focusing on healthcare investments in India and South East Asia. Before joining Quadria Capital, Nav was the Managing Director at Fosun, where he worked on both private and public healthcare investment opportunities across the Asia-Pacific region. Nav started his investment career with Merrill Lynch in Hong Kong and moved to UBS Global Asset Management in Singapore before joining Fosun.

Nav holds an MBA from Indian Institute of Management (IIM), Ahmedabad, in India and Bachelor of Technology from Indian institute of Technology (IIT), Kharagpur in India.

Rob Korom

Chief Medical Officer, Penda Health

Rob Korom, MD, is Chief Medical Officer of Penda Health, a tech-enabled network of primary care clinics in Kenya serving over 1,000 patients daily across Nairobi. He leads clinical quality, AI-driven decision support, and digital innovation to advance Penda’s mission of becoming the most trusted healthcare provider in Africa.

Kwok Ming Lee

Group Director (Ageing Planning Office), Ministry of Health

Mr. Lee Kwok Ming was appointed Group Director of the Ageing Planning Office in the Ministry of Health on 9 October 2023. He oversees the development and implementation of the national ageing agenda, to bring about the national vision of opportunities, communities and a city for all ages. This whole-of-government work spans a wide range of areas including Age Well SG, aged care services, senior housing, seniors health & wellness and ageing research & development.

Kwok Ming’s public service career started in 2008 at the Income Security Policy Division in the Ministry of Manpower. He was responsible for formulating policies, including those related to the Central Provident Fund (CPF), to enhance the retirement adequacy of Singaporeans. Following that he served in a succession of portfolios, including Reserves and Investment at the Ministry of Finance, Land Transport at the Ministry of Transport. In 2019, he returned to the Ministry of Manpower as the Director (Retirement Systems) at the Income Security Policy Division where he was driving projects such as strengthening basic work protections for Platform Workers as well as the development of the Majulah Package.

Kwok Ming graduated from Carnegie Mellon University with a B. Sci. Electrical & Computer Engineering with Additional Major in Economics. He also holds a M. Sci. in Management Science & Engineering from Stanford University and an MBA from INSEAD. Kwok Ming is married with a son and a daughter.

Phin Peng Lee

Acting Program Director, Singapore Biodesign

Dr. Lee Phin Peng is currently serving as the Programme Director for Singapore Biodesign, which is the national platform for health and medtech innovation talent development, and the Lead for MedTech at A*STAR. Dr. Lee also holds an adjunct Assistant Professor position at the Duke-NUS Medical School.

Dr. Lee is passionate about health and medtech innovation and has been building national-level programmes and initiatives related to talent development, sustaining project pipelines, and accelerating startups. Dr. Lee has been directly involved with raising more than $110M in funding for national programmes. He is also actively involved in mentoring programmes for various accelerators and venture building programmes. Dr. Lee is a certified adult educator who has trained researchers, healthcare professionals, and corporates in Design Thinking and the Biodesign methodology.

Dr. Lee holds a PhD in Bioengineering from the University of California, San Francisco – Berkeley and a BSc in Biomedical Engineering from Brown University. He completed his post-doctoral training at the Stanford School of Medicine under the Singapore-Stanford Biodesign Innovation Fellowship.

Daria Lemann-Blumenthal

Chief Executive Officer, Nanodrops

Daria Lemann-Blumenthal is the CEO of NanoDrops, a MedTech company pioneering a breakthrough vision correction technology that eliminates the need for reading glasses. Prior to joining NanoDrops, Daria was the co-founder and CEO of BELKIN Vision, which was acquired by Alcon in 2024 for $466 million, after developing a laser-based glaucoma treatment. She previously served as the CEO of Ein Tal Eye Center, Israel's largest ophthalmic care facility, and led its acquisition. Daria has spent five years of her career in Canada and the USA. She holds an LLB from the Hebrew University of Jerusalem and an Executive MBA from Tel Aviv University, both awarded with Dean’s Honors.

Chwee Teck Lim

Director, NUS Institute for Health Innovation & Technology (iHealthtech)

Professor Chwee Teck Lim is the NUSS Chair Professor and Director of the Institute for Health Innovation and Technology at the National University of Singapore. He is also the Founding Director of the Singapore Health Technologies Consortium, a national initiative. He conducts research in human disease mechanobiology and develops innovative medical technologies for healthcare applications. Prof Lim has co-authored over 500 journal articles and delivered over 550 invited talks. He is also a serial entrepreneur having cofounded six startups with one public listed in 2018. Prof Lim is globally recognised for his distinguished achievements by the over 100 research awards and honors including the Nature Lifetime Achievement Award for Mentoring in Science, Otto Schmitt Award, Highly Cited Researcher, Asia’s Most Influential Scientist Award, ASEAN Outstanding Engineering Achievement Award, Asian Scientists 100, Credit Suisse Technopreneur of the Year Award, Wall Street Journal Asian Innovation Award and the President's Technology Award. He is also an Elected Fellow of 9 academies including the UK Royal Society, US National Academy of Inventors, ASEAN Academy of Engineering and Technology, Singapore National Academy of Science, Academy of Engineering, Singapore and Institution of Engineers, Singapore among others.

Colin Lim

Chief Information and Chief Data Officer, Ministry of Health (MOH)

Colin is the Chief Information and Chief Data Officer at the Singapore Ministry of Health. He is concurrently Chief, Planning and National Community Programmes at Synapxe, Singapore’s national health technology agency. His experience spans the private (mobilityX, a startup funded by SMRT and Toyota Tsusho, SMRT and IBM UK) and public (Singapore Administrative Service - Ministries of Home Affairs, Manpower and Transport as well as the Land Transport Authority) sectors. He graduated from the London School of Economics and Oxford University.

Yong Liu

Deputy Director of Computing and Intelligence, A*STAR Institute of High Performance Computing

Dr Liu Yong is Deputy Department Director, Computing & Intelligence Department at Institute of High Performance Computing (IHPC), A*STAR, Singapore. He is also Adjunct Associate Professor at Duke-NUS Medical School, NUS and Adjunct Principal Investigator at Singapore Eye Research Institute (SERI).

Being passionate on the potential of AI on healthcare, he has led multiple research projects in multimodal machine learning, medical imaging analysis, especially AI for digital ophthalmology and other areas in healthcare. Together with clinicians, he has been awarded large scale programme and multiple grants as PI in the area of AI for healthcare. He and his team have been awarded multiple grants from AI SG, NMRC, IAF-PP, and NHIC. He and his team have also published top tier papers in New England Journal of Medicine, Lancet Digital Health, Nature Aging, Ophthalmology, Neurology, Annals of Neurology, and also top-tier AI papers (AAAI, CVPR, IJCAI, MICCAI). He has won the Nation Award (Covid-19) Commendation Medal. His papers received Best Paper Award at REMIA workshop with 2022 MICCAI, Best Paper Award at BeyondLabeler Workshop on International Joint Conference on Artificial Intelligence (IJCAI) 2016. He and his team has also won the 3rd Place GAMMA Challenge in MICCAI 2021, the NSCC Outstanding HPC Innovation Award 2017, and the first prize of Rakuten TV recommendation Challenge 2015.

Andrea Britta Maier

Oon Chiew Seng Professor in Medicine, Healthy Ageing and Dementia Research, NUS Yong Loo Lin School of Medicine

Andrea Maier (1978), a Fellow of the Royal Australasian College of Physicians (FRACP), graduated in Medicine (MD) 2003 from the University of Lübeck (Germany), was registered 2009 in The Netherlands as Specialist in Internal Medicine-Geriatrics and was appointed Full Professor of Gerontology at Vrije Universiteit Amsterdam (The Netherlands) in 2013. She was the head of Geriatrics at the Vrije Universiteit Medical Center from 2012 to 2016. From 2016 to early 2021 Professor Maier served as Divisional Director of Medicine and Community Care at the Royal Melbourne Hospital, Australia, and as Professor of Medicine and Aged Care at the University of Melbourne, Australia.

Joseph Mocanu

Managing Partner, Verge HealthTech

Dr. Joseph Mocanu is the co-founder and Managing Partner of Verge HealthTech Fund focusing on early-stage healthcare technology companies that make an impact on global health. Prior to this, Joseph was a scientist researching new cancer therapies, a medical device entrepreneur, and a management consultant for Oliver Wyman where he led life sciences and digital health across Asia. He has 19 scientific publications, 3 patents, and has made investments in 46 healthcare technology companies to date. Joseph has a PhD from the University of Toronto, and an MBA from the Richard Ivey School of Business.

Robert Morris

Chief Technology Strategist and Head (Data, Science & Technology), MOH Office for Healthcare Transformation

Robert is the Chief Technology Strategist at MOHT, where he anchors the Data and Technology Enablers. He concurrently serves as Professor at the Yong Loo Lin School of Medicine, National University of Singapore, and as Executive Director of the SIngapore Medical FOundation AI model (SIMFONI) Programme under the Consortium for Clinical Research and Innovation, Singapore.

His current focus is on the application of computer and information sciences, including AI, to transform healthcare.

Until 2017, Robert led all of IBM Research’s Global Laboratories. Prior to that, Robert was also head of the IBM Almaden Research Center (Silicon Valley), where relational database technology and the disk drive were invented. During this time he led the creation of Services Science, research for IBM’s ThinkPad, and Storage Systems. Earlier he also led advanced systems research at TJ Watson Center (New York), including the Deep Blue chess machine, which defeated world champion Garry Kasparov in 1997.

He completed his PhD in Computer Science at the University of California, Los Angeles.

Kah Yean Neo

Senior Director, Tech-Biz at A*STAR Innovation & Enterprise Group, Agency for Science, Technology and Research

Kah Yean is Senior Director, Tech-Biz at A*STAR Innovation & Enterprise Group, leading the industry engagement, technology development and commercialization of therapeutics assets and platforms, biotech and bioprocessing technologies in A*STAR, and supports Market Access at A*STAR Medtech Sector.

Kah Yean’s career spans the breadth of the healthcare industry, having spent time in pharmaceuticals, diagnostics and consumer healthcare. She spent most of her time in general management, commercial and strategic roles in Asia-Pacific and Global markets with a strong track record for successful business turnaround and people development.

Kah Yean is the former President of the Singapore Association of Pharmaceutical Industries and is actively engaged in advising companies and mentoring startups. She holds a Bachelor of Science for Biochemistry and Chemistry and an MBA for University of Hull, U.K, and is an alumna of Smith College, Massachusetts and University of Notre-Dame, Indiana, through various executive leadership programs.

Wai Hoe Ng

Group Chief Executive Officer, SingHealth

Professor Ng Wai Hoe is the Group Chief Executive Officer of SingHealth and Professor at Duke-NUS Medical School. He was previously Deputy Group Chief Executive Officer (Strategy & Planning) of SingHealth, Chief Executive Officer of Changi General Hospital (CGH), Medical Director/Chief Executive Officer of the National Neuroscience Institute (NNI), Academic Chair of the SingHealth Duke-NUS Neuroscience Academic Clinical Programme and Deputy Chair of the SingHealth Medical Board.

He has present and past administrative responsibilities as Member of the Duke-NUS Governing Board, Executive Committee Member of the National Medical Research Council (NMRC), Member of the Human Health Potential (HHP) Executive Committee of the National Research Foundation (NRF), Member of the Medical Device Advisory Committee (MDAC) with the Health Sciences Authority (HSA) Singapore, Member of the Medical Technology Advisory Council (MTAC) of the Ministry of Health (MOH), Co-Chairperson of the Workgroup to Review the Taking of Informed Consent and Singapore Medical Council Disciplinary Process with the MOH and Panel of Chairmen of Disciplinary Tribunal with the Singapore Medical Council (SMC).

His clinical practice focuses on neurosurgical oncology, epilepsy surgery and stereotactic and functional neurosurgery. He was past Chairman of the Neurosurgery Residency Advisory Committee (RAC) and past Chairman of the Chapter of Neurosurgeons (Singapore).

Kee Yuan Ngiam

Head, Artificial Intelligence Office, National University Health System

Prof Ngiam Kee Yuan is Head of the Artificial Intelligence Office, National University Health System. He is also Adjunct Professor at the Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore. In his clinical role, he is Head and Senior Consultant at the Division of General Surgery (Thyroid & Endocrine Surgery) at the National University Hospital, specialising in Thyroid and Endocrine surgical disorders. His special interests are in thyroid and endocrine surgery, robotic thyroid surgery, AI and technology implementation in healthcare.

Rajeev Rikhye

Research Scientist, Google DeepMind

Dr. Rajeev Rikhye is a Research Scientist at Google DeepMind, where he leads post-training efforts dedicated to scientific factuality. At GDM, he leads initiatives to ensure that Gemini models responsibly source and cite the most relevant and accurate information for complex health, science, and educational queries. His experience in health AI includes spearheading significant consumer health features. During his tenure at Google Research, he directed the successful launch of a novel dermatology experience on Google Lens and developed a new LLM-based health data analysis agent for Fitbit. Originally from Singapore, Rajeev trained in Biomedical Engineering at Imperial College London before earning his Ph.D. in Computational Neuroscience from MIT. He remains an active contributor to the scientific community, having published numerous papers that bridge the intersection of health, neuroscience, and artificial intelligence. In his spare time, he enjoys spending time with his two young boys and his overgrown dog.

Alina Rodriguez

Professor of Psychological Medicine, NUS Yong Loo Lin School of Medicine

An active multidisciplinary scientist and educator for over two decades, Rodriguez embeds evidence-base into teaching at all university levels, supervising students to PhD completion, and mentoring post-docs. Spanning four countries, her research includes maternal and child health, mental health, neurodevelopment, and obesity. She is one of the leads for the Integrative Adolescence Research Programme (IARP) at A*STAR IHDP, which was developed to identify causal risk factors impacting adolescent mental health and to investigate the interplay between mental and physical health. The ultimate goal is to design and implement targeted prevention and intervention programmes.

Rodriguez earned her PhD from Uppsala University Sweden in psychology. She then trained extensively in public health and epidemiology at Imperial College London as a recipient of the prestigious fellowship from the Swedish Governmental Agency for Innovation Systems. Her unique background enables her to carry out international level research in pregnancy and life course development, disease risk from a socio-behavioural perspective, and contribute to the understanding of the crossover between mental and physical health.

Besides receiving the Knut & Alice Wallenberg Foundation for Promising Young Women in Research, Rodriguez is also a chartered member of the British Psychological Society, including the Division of Neuropsychology, Division of Academics, Researchers & Teachers in Psychology, Division of Clinical Psychology and the Faculty for Children, Young People and their Families; and currently serves on the Scientific and Medical Advisory Committee of Unlocking ADHD in Singapore.

Martin Saerbeck

Founder & CTO, AIQURIS

Martin is a leading voice in AI assurance and systems design. As former CTO of TUV SUD Digital Service, he pioneered one of the first certification-ready models for AI through the TUV SUD AI Quality Framework. He holds a PhD in Computer Science, and his work spans robotics, IoT, and applied machine learning. As a contributor to ISO, IEEE SA, and DIN committees, Martin turns turning emerging standards into robust, real-world assurance systems.

Nigam H. Shah

Chief Data Scientist, Stanford Health Care, and Professor of Medicine, and of Biomedical Data Science, Associate Dean (School of Medicine), Associate Director (Stanford Center for Biomedical Informatics Research), Stanford University

Dr. Nigam Shah is Professor of Medicine at Stanford University and Chief Data Scientist for Stanford Health Care. He is a world-renowned scientist and entrepreneur with deep expertise in applying machine learning and artificial intelligence (AI) to analyze diverse health data, including electronic health records, claims, and wearables. In his Chief Data Scientist role, he oversees the responsible use of AI for advancing disease understanding and improving clinical care delivery across Stanford Health Care. In 2018, he created the USA's only bedside consultation service, to provide clinicians with on-demand patient outcome summaries. This service was cited in Congressional testimony and was spun out as the independent company Atropos Health in 2021.

Shah's research is highly influential, with over 350 publications (h-index 94) in journals such as JAMA and the New England Journal of Medicine, receiving over 43,000 citations. As an entrepreneur, he holds nine patents and co-founded three companies that collectively raised over $100 million. He is a dedicated educator, teaching in multiple graduate classes at Stanford University and in an AI in Healthcare Specialization to over 60,000 students online. He is a member of the National Academy of Medicine’s Digital Learning Collaborative as well as a cofounder of the coalition for health AI, which provides guidelines for the responsible use of AI in healthcare.

Joe Sim

Group Chief Executive Officer, NHG Health

Prof Joe Sim is the Group Chief Executive Officer (GCEO) of NHG Health, one of Singapore’s three public healthcare clusters comprising an integrated system of polyclinics, acute care and tertiary hospitals, and national specialty centres. Prof Sim oversees NHG Health’s strategies to improve access to and equity in healthcare through innovation, evidence-based research, technology and meaningful collaborations.

Before joining NHG Health, Prof Sim was the Group Chief Operating Officer and Acting GCEO of IHH Healthcare Berhad (listed in both Singapore Exchange and Bursa Malaysia) where he was responsible for its integrated healthcare businesses comprising more than 80 hospitals and multiple business units across 10 countries. He joined IHH in 2017 as the CEO of Malaysia Operations Division, overseeing operations and management for IHH’s business units in Malaysia covering a network of 15 Gleneagles and Pantai hospitals and ancillary services such as Pantai Integrated Rehab and Pantai Premier Pathology.

Prior to IHH, Prof Sim was Deputy Chief Executive of the National University Health System (NUHS), another public healthcare cluster in Singapore. Prof Sim graduated with First Class Honours in Bachelor of Arts in Electronic and Information Science from Cambridge University, and holds a Master in Public Administration from Harvard University.

Tom Smoot

Country Lead (Singapore), Epic Systems

Tom has spent 15 years at Epic leading large-scale healthcare IT transformation. After more than a decade working with health systems across the United States, Tom moved to Europe in 2023, where he led implementations with academic medical centres in Switzerland and the Netherlands and also witnessed firsthand the early rollout of Epic's AI capabilities in live clinical environments.

In early 2025, Tom relocated to Singapore as Epic's Country Lead, taking on responsibility for all of Epic's operations in the region. He oversees ongoing partnerships with NUHS and NHG Health - both live on Epic - while leading two concurrent implementations with SingHealth and the Singapore Armed Forces, which will mark the first time Epic has been deployed simultaneously across a national public health system and a defence medical system. Tom is actively engaged with the PHIs and the Ministry of Health on building a path to bring Epic's native generative AI capabilities to Singapore.

Cher Heng Tan

Co-Chair, National AI Medical Imaging Platform (AimSG), Chief Medical Scientist, Centre of AI in Medicine (NTU), and Senior Consultant, Department of Diagnostic Radiology, Tan Tock Seng Hospital

A/Professor Cher Heng Tan graduated with MBBS (Singapore) and FRCR (UK). He completed his Abdominal Imaging Fellowship at MD Anderson Cancer Center, and thereafter, Executive MBA from Insead. He is presently Senior Consultant with the Department of Diagnostic Radiology at Tan Tock Seng Hospital and Chief Operating Officer at Woodlands Hospital. He had formerly served as Assistant Chairman Medical Board (Clinical Research and Innovation) and NHG Health’s Chief Research and Innovation Officer.

He is concurrently Assistant Dean (Clinical Research) for the Lee Kong Chian School of Medicine and is involved in the setting up of the Academic Health System between NHG and LKCMedicine-NTU Singapore, as Director of the joint Academic Partnerships Office.

Cher Heng currently leads NHG Health’s efforts in implementation of AI in Radiology as co-Chair for the national imaging AI platform (AimSG) and plays a bridging role with NTU as Chief Medical Scientist of its Centre of AI in Medicine.

Sze Wee Tan

Advisor, Ecosystem Enablement (Healthcare & Lifescience), Temasek Singapore Pte Ltd

Education and Training: Professor Tan graduated with MBBS from National University of Singapore (NUS), and attained his MBA from Warwick University, UK. He attended the Stanford Executive Programme at the Stanford University’s Graduate School Business, and was awarded a certificate of completion for the Senior Fellowship in Public Service Programme, Lee Kuan Yew School of Public Policy in Singapore. Prof Tan also attended the Executive Leadership Programme from the Singapore Civil Service College. He is an affiliate member of the Faculty of Pharmaceutical Medicine, Royal College of Physicians, UK. He is a registered medical practitioner with the Singapore Medical Council.

Leadership Appointment: Prof Tan Sze Wee is currently Advisor to Temasek Singapore Pte Ltd. Temasek is a global investment company headquartered in Singapore with a multinational staff of over 900 people. Prof Tan will be supporting Temasek at BioSparc in Suzhou. This is a China-Singapore Life Sciences Park, which Temasek is working on with Suzhou Industrial Park. It aims to build on the SIP’s strengths in the biomedical sector, providing research and development centres and manufacturing facilities to advance cutting-edge innovations from drug development and medical devices to artificial intelligence-driven medical technologies.

Between 2009 to 2025, Prof Tan served various leadership roles in the Agency for Science, Technology and Research (A*STAR), which is Singapore's lead public sector R&D agency. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with over 6,000 staff within 17 research entities and national platforms primarily located in Biopolis and Fusionopolis.

Prof Tan’s career in A*STAR started in 2009. He was first appointed as Programme Director of the A*STAR Medical Technology initiative in Science and Engineering Research Council (SERC), that led in the partnership with Stanford BioDesign @ Stanford University, and Center for Integration of Medicine & Innovative Technology (CIMIT) in Massachusetts General Hospital in Boston, USA. Prof Tan was subsequently appointed as Director (SERC), where he oversaw all SERC cluster-led research and development (R&D). From 2012 to 2015, Prof Tan was Deputy Executive Director (DED), Biomedical Research Council (BMRC) and his cross-Council experience enabled A*STAR to engage companies across industry sectors.

In 2016, Prof Tan was appointed ED, SERC and was subsequently redesignated as Assistant Chief Executive (ACE), SERC in 2019. As ACE SERC, Prof Tan drove the implementation of strategic plans and initiatives set for A*STAR in the Science and Engineering areas. Prof Tan was appointed ACE, Innovation and Enterprise as well as Acting Chief Executive of A*ccelerate Technologies Pte Ltd in 2020. He aligned A*STAR industry engagement, licensing and venture creation value chain among the A*STAR Research Institutes and the National Platforms. This is to drive efforts to translate A*STAR’s R&D to market so as to enable research-fuelled economic and societal impact.

From 2023 to 2025, Prof Tan was appointed ACE BMRC. BMRC supports, oversees and coordinates public sector biomedical research and development activities in Singapore to cultivate a thriving biomedical cluster. At BMRC, he oversaw the development of core research capabilities in bioprocessing, genomics and proteomics, molecular and cell biology, bioengineering and nanotechnology, and computational biology. Prof Tan also served on the governance committee of National Platforms Diagnostic Development Hub (DxDHub), Experimental Drug Development Centre (EDDC) and Medtech Catapult.

Prior to these roles, Prof Tan was the Managing Director and Chief Executive Officer of Rockeby biomed Limited from 2001 to 2009. He was the Asia-Pacific Associate Regional Medical Director for Mead Johnson Nutritional’s, a division pf Bristol-Myers Squibb Company from 1997 to 2001.

Academic, Clinical and Innovation Focus: Professor Tan constantly promotes international research, innovation and enterprise partnership between Singapore, A*STAR and its key scientific, industry and venture building partners across the world. He has forged bilateral research partnership programmes between Singapore and China, Germany, Korea, Japan, New Zealand. He is a speaker at international conferences on topics around medical technologies, AI in Healthtech, and advises academic, corporate and not for profit organisations for wide range of topics. Within A*STAR, he oversaw close to 2,000 research scientists and engineers during his stint at BMRC and SERC, each with annual operating budget of US$300M.

Professional Service: Professor Tan has served on various national committees in Singapore. He is a member of the Board Oversight Committee for Advanced Cell Therapy and Research Institute, Singapore (ACTRIS). He is a board member of the Singapore Eye Research Institute (SERI) as well as a member of its Incubator Advisory Board for the SERI Ophthalmic Technologies Incubator Phase II Program. He is a council member of the Singapore Medical Association (SMA), as well as a board director for SMA Pte Ltd. Prof Tan is also the Chairman of Unlocking ADHD Ltd.

Awards & Honours: Professor Tan was a former Nominated Member of Parliament of Singapore, and is a recipient of the Singapore Public Administration Medal (Silver) as well as the Singapore (Covid-19) Public Administration Medal (Silver). He has also received the Friend of Labour Award.

Yuhua Tan

Deputy Director, Quality Systems, AE and Compliance Branch, Medical Devices Cluster, Health Sciences Authority, Singapore

Yuhua is Deputy Director of Quality Systems, AE and Compliance Branch at the Medical Devices Cluster, Health Sciences Authority, Singapore. With over 15 years of experience in Medical Device Regulations, she oversees adverse events reporting, dealers licensing, compliance programmes, and ISO 13485 and GDPMDS witness audit programmes. She played a key role in the IMDRF UDI Working Group, contributing to the "Unique Device Identification System Application Guide" and leads Singapore's UDI implementation. She serves as a member of IMDRF Working Groups on Quality Management Systems and Singapore's National Mirror Working Group on ISO/TC 210 Quality Management.

Choon Hong Tay

Chief Executive Officer, Health Promotion Board

Mr Tay Choon Hong is the Chief Executive of the Health Promotion Board (HPB), which is part of the Ministry of Health in Singapore. HPB’s role is to empower individuals to take ownership of their health, towards its vision of a nation of healthy people. To achieve this, HPB works with a wide spectrum of 3P partners and stakeholders to build a supportive ecosystem that enables Singaporeans to engage in healthy lifestyle activities, and lead healthier lives.

Prior to this, Mr Tay was the Senior Director (Youth) in the Ministry of Culture, Community & Youth, and concurrently Deputy Chief Executive of the National Youth Council. He led the review of policies and programmes aimed at developing youths to be future-ready and committed to the nation. Mr Tay also served in the Public Service Division, where he oversaw the Public Sector Transformation change movement aimed at strengthening capabilities in innovation, collaboration, service delivery, employee engagement and citizen engagement.

Mr Tay previously served in the National Population and Talent Division, the Ministry of Manpower, and the Ministry of Home Affairs.

Mr Tay graduated from Carnegie Mellon University with dual Bachelor’s in Electrical and Computer Engineering, and Economics. He also holds a Master of Science in Management from the Stanford Graduate School of Business.

Vy Tran

President, Asia Pacific and Japan (APJ), Siemens Healthineers

Vy Tran is a healthcare leader with a broad range of experience in medtech, medical devices and oncology.

As the President of Asia Pacific and Japan (APJ), Vy is responsible for one of the fastest growing and dynamic regions in Siemens Healthineers. She leads a passionate team of more than 5,000 Healthineers with a strong purpose of pioneering breakthroughs in healthcare, for everyone, everywhere, sustainably.

Since becoming the commercial regional head in 2022, Vy has led several strategic and digital transformation initiatives with a laser focus to build a more patient and customer-centric organization that brings high value care through a broad portfolio of healthcare offerings that alleviates key disease burdens and increases access to care in Asia.

In addition, Vy is responsible for the strategy, P&L and market growth for APJ and a member of the Siemens Healthineers Global Leadership Committee. Vy also sits on the Board of Asia Pacific Medical Technology Association (APACMed) and US-India Strategic Partnership Forum.

Prior to Siemens Healthineers, Vy served in leadership roles at Varian including Chief Compliance Office where she led policy development and regulatory reform. She was also instrumental in sharpening Varian’s focus on becoming a leading cancer care company through strategic acquisitions, divestments and was involved in the combination of Varian and Siemens Healthineers in 2021.

Vy is passionate about bringing access and equity to patients and her personal mission of promoting diversity, equality and empowering people to reach their potential.

Vy holds a bachelor’s degree of Science from Santa Clara University and a Juris Doctorate from Lincoln Law School. In line with her interest in early childhood education, Vy is part of the Board of Directors for the Children’s Discovery Museum of San Jose and serves as the Board Secretary.

Originally from Silicon Valley, Vy lives in Singapore, with her husband and two teenage daughters.

Lawrence Wee

Director, Business and Ecosystems, Infocomm Media Development Authority

Dr. Lawrence Wee is currently Director of the Business and Ecosystems division at IMDA. His team is responsible for driving strategic collaborations to catalyze the exploitation and adoption of AI and emerging technologies for enterprises.

He started his career in public sector research and development when he founded the Healthcare and Biomedical Analytics Laboratory at the Institute of Infocomm Research (I2R), which focused on building deep capabilities in machine learning for biomedicine and healthcare. After the stint at I2R, he moved on to Zuellig Pharma where he took on the role of Chief Data Scientist and led the development of institutional data science capabilities across APAC region. Following that, he joined Allianz Asia-Pacific, where he was responsible for building the regional APAC healthcare data science capabilities across life and health insurance business units. Thereafter, he returned to public service at the Ministry of Health where he had the opportunity to drive strategy and capability development in AI and emerging technologies for the public health sector.

He is an Associate Faculty at the Singapore University of Social Sciences, and was previously the President of the Association for Medical and Bio-informatics Singapore (AMBIS), and vice-chair of the Chinese-American Pharmaceutical Society (CABS) Singapore chapter.

He received his Ph.D. in Computational Biology from the National University of Singapore.

Tien Yin Wong

Professor & Senior Vice Chancellor, Tsinghua Medicine and Vice Provost, Tsinghua University

Professor Tien Yin Wong is a physician-scientist-innovator and the Senior Vice-Chancellor of Tsinghua Medicine and Vice-Provost of Tsinghua University, China. He has worked and held senior leadership roles in Singapore and Australia, including at the National University of Singapore, SingHealth Duke-NUS Medical School, Singapore National Eye Centre, and University of Melbourne.

Prof Wong is a practicing retinal specialist, with a research portfolio on retinal diseases, ocular imaging, AI and digital technology. He has published >1,600 peer-reviewed papers (H-index >200, highly cited researcher 2020-2025), given >600 invited named, plenary and symposium lectures, and received >US$100 million in grant funding. Prof Wong has been recognized with multiple international awards, including Arnall Patz Medal (Macula Society), Jose Rizal Medal (Asia Pacific Academy of Ophthalmology) and Friedenwald Award (ARVO). He has received Singapore’s President’s Science and Technology Award. He is an elected international (foreign) member of the US National Academy of Medicine and the Australian Academy of Health and Medical Sciences. He is also an elected fellow of the UK Royal Society.

Shuicheng Yan

Distinguished Professor (Practice) at the School of Computing, National University of Singapore

Prof. Yan Shuicheng is currently a Distinguished Professor (Practice) at the School of Computing, National University of Singapore. He previously served as the Group Chief Scientist at Sea Group and has held several other notable industry positions. Prof. Yan is a Fellow of the Singapore Academy of Engineering, AAAI, ACM, IEEE, and IAPR. His research focuses on computer vision, machine learning, and multimedia analysis. He has also been recognised as one of the World's Highly Cited Researchers for ten years. Under Prof. Yan's leadership, his team has secured ten first-place or honorable-mention accolades in two flagship competitions: Pascal VOC and ImageNet (ILSVRC). Additionally, his team has earned more than ten best paper and best student paper awards, including a remarkable grand slam at ACM Multimedia, a premier conference in multimedia research, with three Best Paper Awards, two Best Student Paper Awards, and one Best Demo Award.